uPAR as a Glioma Imaging Target [PDF]
Journal of Nuclear Medicine, 2015 Gliomas account for 70% of primary brain tumors ([1][1]). Among the various types of glioma, glioblastoma is the most aggressive astrocytic tumor, being classified grade IV by the World Health Organization ([2][2]). Although CT and MRI are indispensable in providing morphologic information,
Kenji, Hirata, Nagara, Tamaki
openaire +2 more sources
Generation of Antibodies to the Urokinase Receptor (uPAR) by DNA Immunization of uPAR Knockout Mice: Membrane‐Bound uPAR is Not Required for an Antibody Response [PDF]
Scandinavian Journal of Immunology, 2003 AbstractThe urokinase receptor (uPAR) is a glycolipid‐anchored cell surface glycoprotein that plays a central role in extracellular proteolysis during tissue remodeling processes including cancer invasion. Furthermore, uPAR is found on the surface of both dendritic cells (DCs) and T cells, and has been proposed to play a role in DC‐induced T‐cell ...
J, Pass +4 more
openaire +2 more sources
TLR4 Response to LPS Is Reinforced by Urokinase Receptor
Frontiers in Immunology, 2020 GPI-anchored uPAR is the receptor for the extracellular serine protease urokinase-type plasminogen activator (uPA). Though uPAR role in inflammatory processes is documented, underlying mechanisms are not fully understood.
Yulia Kiyan +8 more
doaj +1 more source
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes [PDF]
, 2012 mRNA levels of the urokinase receptor splice variant uPAR-del4/5 are associated with prognosis in breast cancer. Its overexpression in cancer cells affects tumor biologically relevant processes.
Sato, Sumito +11 more
core +1 more source
Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells
, 2022 The 3′ untranslated region (3′UTR) of the urokinase (uPA) receptor (uPAR) mRNA can act as a competitive endogenous RNA (ceRNA) in acute myeloid leukaemia (AML) cells, promoting the expression of pro-tumoral targets, including uPAR.
Li Santi A. +5 more
core +2 more sources
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87) [PDF]
, 2001 Urokinase-type plasminogen activator (uPA) represents a central molecule in pericellular proteolysis and is implicated in a variety of physiological and pathophysiological processes such as tissue remodelling, wound healing, tumor invasion, and ...
Kellermann, Josef +10 more
core +1 more source
Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator Receptor [PDF]
, 2011 Background: Urokinase-type plasminogen activator (uPA) has recently been implicated in the pathogenesis of ischemia-reperfusion (I/R) injury. The underlying mechanisms remain largely unclear.
Paul J. Declerck +27 more
core +1 more source
BMC Cancer, 2017 Background Urokinase plasminogen activator (uPA) receptor (uPAR) is up-regulated at the invasive tumour front of human oral squamous cell carcinoma (OSCC), indicating a role for uPAR in tumour progression.
Synnove Norvoll Magnussen +10 more
doaj +1 more source
Efferocytosis: another function of uPAR
Blood, 2009 uPAR, the receptor for urokinase plasminogen activator, is a regulator of the uptake by macrophages of apoptotic neutrophils (efferocytosis). Its role and mechanism appear to be complex and possibly controversial.
Blasi, Francesco, Sidenius, Nicolai
openaire +3 more sources
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis [PDF]
, 2003 Pemphigus is an autoimmune blistering disease of the skin and mucous membranes. It is caused by autoantibodies directed against desmosomes, which are the principal adhesion structures between epidermal keratinocytes.
Besch, R. +19 more
core +2 more sources